MKP10241

MKP10241 is a **first-in-class, orally administered small molecule G protein-coupled receptor 119 agonist (GPR119 agonist)** developed by Mankind Pharma for the treatment of type 2 diabetes mellitus and obesity. It acts by **elevating plasma insulin and GLP-1 (glucagon-like peptide-1) levels**—stimulating postprandial insulin and incretin secretion in a glucose-dependent manner. This dual mechanism helps reduce plasma glucose and glycated hemoglobin while minimizing the risk of hypoglycemia, making it distinct from existing therapies for type 2 diabetes. The drug has demonstrated efficacy in preclinical and early clinical studies, and is currently in **Phase 2 clinical development** for both obesity and type 2 diabetes[1][2][3][4][5][6][7][9][10].

Other names

MKP-10241MKP10241MKP 10241